Mirum Pharmaceuticals, Inc.

NasdaqGM MIRM

Mirum Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2024: USD 320.12 M

Mirum Pharmaceuticals, Inc. Total Non-Current Liabilities is USD 320.12 M for the quarter ending September 30, 2024, a 4.31% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Mirum Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2023 was USD 306.90 M, a 113.64% change year over year.
Mirum Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2022 was USD 143.65 M, a 11.89% change year over year.
Mirum Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2021 was USD 128.38 M, a 4,455.86% change year over year.
Mirum Pharmaceuticals, Inc. Total Non-Current Liabilities for the quarter ending September 30, 2020 was USD 2.82 M, a 142.72% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

NasdaqGM: MIRM

Mirum Pharmaceuticals, Inc.

CEO	Mr. Christopher Peetz
IPO Date	July 18, 2019
Location	United States
Headquarters	950 Tower Lane
Employees	311
Sector	Healthcare
Industries Biotechnology Clinical Trials Drugstores & Retail Pharmacies Glass Pharmaceuticals

Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Key trends

Past 5 years